Somatostatin Dramatically Stimulates Growth Hormone Release from Primate Somatotrophs Acting at Low Doses Via Somatostatin Receptor 5 and Cyclic AMP

Journal of Neuroendocrinology

Volumn 24, Issue 3, 2012, Pages 453-463

  Cordoba Chacon J ^a,b   Gahete, M D ^a,b,c   Culler, M D ^d   Castano J P ^a   Kineman, R D ^b   Luque, R M ^a,b,c  

^a UNIVERSITY OF CÓRDOBA   (Spain)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c JESSE BROWN VA MEDICAL CENTER   (United States)

^d IPSEN   (France)

Author keywords

Agonists antagonists; CAMP; Cortistatin; Growth hormone; Normal pituitary physiology; Somatostatin; Sst5

Indexed keywords

ADENYLATE CYCLASE; CORTISTATIN; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; GHRELIN; GROWTH HORMONE RELEASING FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROLACTIN; SOMATOSTATIN; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 5;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL TYPE; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; GROWTH HORMONE RELEASE; GROWTH HORMONE SECRETING CELL; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; HYPOPHYSIS CELL; LOW DRUG DOSE; MALE; NONHUMAN; PAPIO ANUBIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; CELLS, CULTURED; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GROWTH HORMONE; PAPIO; PITUITARY GLAND; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, SOMATOSTATIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SOMATOSTATIN;

EID: 84857376637     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/j.1365-2826.2011.02261.x     Document Type: Article

References (55)

1. Ben-Shlomo A, Melmed S. Pituitary somatostatin receptor signaling. Trends Endocrinol Metab 2010; 21: 123-133.
2. Florio T, Thellung S, Corsaro A, Bocca L, Arena S, Pattarozzi A, Villa V, Massa A, Diana F, Schettini D, Barbieri F, Ravetti JL, Spaziante R, Giusti M, Schettini G. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro. Clin Endocrinol (Oxf) 2003; 59: 115-128.
3. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 1998; 19: 717-797.
4. Moller LN, Stidsen CE, Hartmann B, Holst JJ. Somatostatin receptors. Biochim Biophys Acta 2003; 1616: 1-84.
5. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999; 20: 157-198.
6. Shimon I, Taylor JE, Dong JZ, Bitonte RA, Kim S, Morgan B, Coy DH, Culler MD, Melmed S. Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J Clin Invest 1997; 99: 789-798.
7. Tannenbaum GS, Epelbaum J. Somatostatin. In: Kostyo JL, ed. The Endocrine System: Hormonal Control of Growth. New York, NY: Oxford University Press, 1999: 221-265.
8. Shimon I, Yan X, Taylor JE, Weiss MH, Culler MD, Melmed S. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest 1997; 100: 2386-2392.
9. Gahete MD, Duran-Prado M, Luque RM, Martinez-Fuentes AJ, Quintero A, Gutierrez-Pascual E, Cordoba-Chacon J, Malagon MM, Gracia-Navarro F, Castano JP. Understanding the multifactorial control of growth hormone release by somatotropes: lessons from comparative endocrinology. Ann NY Acad Sci 2009; 1163: 137-153.
10. Luque RM, Park S, Kineman RD. Role of endogenous somatostatin in regulating GH output under basal conditions and in response to metabolic extremes. Mol Cell Endocrinol 2008; 286: 155-168.
11. Baranowska B, Chmielowska M, Wolinska-Witort E, Bik W, Baranowska-Bik A, Martynska L. Direct effect of cortistatin on GH release from cultured pituitary cells in the rat. Neuro Endocrinol Lett 2006; 27: 153-156.
12. Bossis I, Porter TE. Identification of the somatostatin receptor subtypes involved in regulation of growth hormone secretion in chickens. Mol Cell Endocrinol 2001; 182: 203-213.
13. Castaño JP, Delgado-Niebla E, Duran-Prado M, Luque RM, Sanchez-Hormigo A, Gracia-Navarro F, Garcia-Navarro S, Kineman RD, Malagon MM. New insights in the mechanism by which SRIF influences GH secretion. J Endocrinol Invest 2005; 28(5 Suppl): 10-13.
14. Luque RM, Duran-Prado M, Garcia-Navarro S, Gracia-Navarro F, Kineman RD, Malagon MM, Castano JP. Identification of the somatostatin receptor subtypes (sst) mediating the divergent, stimulatory/inhibitory actions of somatostatin on growth hormone secretion. Endocrinology 2006; 147: 2902-2908.
15. Luque RM, Peinado JR, Gracia-Navarro F, Broglio F, Ghigo E, Kineman RD, Malagon MM, Castano JP. Cortistatin mimics somatostatin by inducing a dual, dose-dependent stimulatory and inhibitory effect on growth hormone secretion in somatotropes. J Mol Endocrinol 2006; 36: 547-556.
16. Comuzzie AG, Cole SA, Martin L, Carey KD, Mahaney MC, Blangero J, VandeBerg JL. The baboon as a nonhuman primate model for the study of the genetics of obesity. Obes Res 2003; 11: 75-80.
17. Kineman RD, Luque RM. Evidence that ghrelin is as potent as growth hormone (GH)-releasing hormone (GHRH) in releasing GH from primary pituitary cell cultures of a nonhuman primate (Papio anubis), acting through intracellular signaling pathways distinct from GHRH. Endocrinology 2007; 148: 4440-4449.
18. McClure HM. Nonhuman primate models for human disease. Adv Vet Sci Comp Med 1984; 28: 267-304.
19. Rohrer SP, Birzin ET, Mosley RT, Berk SC, Hutchins SM, Shen DM, Xiong Y, Hayes EC, Parmar RM, Foor F, Mitra SW, Degrado SJ, Shu M, Klopp JM, Cai SJ, Blake A, Chan WW, Pasternak A, Yang L, Patchett AA, Smith RG, Chapman KT, Schaeffer JM. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science 1998; 282: 737-740.
20. Halem HA, Taylor JE, Dong JZ, Shen Y, Datta R, Abizaid A, Diano S, Horvath T, Zizzari P, Bluet-Pajot MT, Epelbaum J, Culler MD. Novel analogs of ghrelin: physiological and clinical implications. Eur J Endocrinol 2004; 151(Suppl 1): S71-S75.
21. Zatelli MC, Tagliati F, Taylor JE, Rossi R, Culler MD, Degli Uberti EC. Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line tt. J Clin Endocrinol Metab 2001; 86: 2161-2169.
22. Neto LV, Machado Ede O, Luque RM, Taboada GF, Marcondes JB, Chimelli LM, Quintella LP, Niemeyer P Jr, de Carvalho DP, Kineman RD, Gadelha MR. Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly. J Clin Endocrinol Metab 2009; 94: 1931-1937.
23. Luque RM, Gahete MD, Valentine RJ, Kineman RD. Examination of the direct effects of metabolic factors on somatotrope function in a non-human primate model, Papio anubis. J Mol Endocrinol 2006; 37: 25-38.
24. Luque RM, Córdoba-Chacón J, Gahete MD, Navarro VM, Tena-Sempere M, Kineman RD, Castaño JP. Kisspeptin regulates gonadotroph and somatotroph function in non-human primate pituitary via common and distinct signaling mechanisms. Endocrinology 2011; 152: 957-966.
25. O'Carroll AM, Krempels K. Widespread distribution of somatostatin receptor messenger ribonucleic acids in rat pituitary. Endocrinology 1995; 136: 5224-5227.
26. Kumar U, Laird D, Srikant CB, Escher E, Patel YC. Expression of the five somatostatin receptor (SSTR1-5) subtypes in rat pituitary somatotrophes: quantitative analysis by double-layer immunofluorescence confocal microscopy. Endocrinology 1997; 138: 4473-4476.
27. Greenman Y, Melmed S. Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J Clin Endocrinol Metab 1994; 79: 724-729.
28. Jiang H, Smith RG. Modification of Ghrelin And Somatostatin Signaling by Formation of GHS-R1a/SSTR5 Heterodimers. The Endocrine Society's 89th Annual Meeting. Toronto, ON: 2007; P9: 299.
29. Duran-Prado M, Malagon MM, Gracia-Navarro F, Castano JP. Dimerization of G protein-coupled receptors: new avenues for somatostatin receptor signalling, control and functioning. Mol Cell Endocrinol 2008; 286: 63-68.
30. Zatelli MC, Ambrosio MR, Bondanelli M, degli Uberti EC. In vitro testing of new somatostatin analogs on pituitary tumor cells. Mol Cell Endocrinol 2008; 286: 187-191.
31. Jaquet P, Saveanu A, Gunz G, Fina F, Zamora AJ, Grino M, Culler MD, Moreau JP, Enjalbert A, Ouafik LH. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. J Clin Endocrinol Metab 2000; 85: 781-792.
32. Kreienkamp HJ, Akgun E, Baumeister H, Meyerhof W, Richter D. Somatostatin receptor subtype 1 modulates basal inhibition of growth hormone release in somatotrophs. FEBS Lett 1999; 462: 464-466.
33. Hubina E, Ruscica M, Nanzer AM, Czirjak S, Goth MI, Grossman AB, Korbonits M. Novel molecular aspects of pituitary adenomas. J Endocrinol Invest 2005; 28(11 Suppl International): 87-92.
34. Castaño JP, Torronteras R, Ramirez JL, Gribouval A, Sanchez-Hormigo A, Ruiz-Navarro A, Gracia-Navarro F. Somatostatin increases growth hormone (GH) secretion in a subpopulation of porcine somatotropes: evidence for functional and morphological heterogeneity among porcine GH-producing cells. Endocrinology 1996; 137: 129-136.
35. Ramirez JL, Gracia-Navarro F, Garcia-Navarro S, Torronteras R, Malagon MM, Castano JP. Somatostatin stimulates GH secretion in two porcine somatotrope subpopulations through a cAMP-dependent pathway. Endocrinology 2002; 143: 889-897.
36. Daniels M, James RA, Harris PE, Turner SJ, Dewar J, Kendall-Taylor P. Actions of L-363, 586, a cyclic hexapeptide analogue of somatostatin, on GH secretion by human somatotrophinoma cells in vitro. Life Sci 1991; 49: 1207-1212.
37. Matrone C, Pivonello R, Colao A, Cappabianca P, Cavallo LM, Del Basso De Caro ML, Taylor JE, Culler MD, Lombardi G, Di Renzo GF, Annunziato L. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs. Neuroendocrinology 2004; 79: 142-148.
38. Murray RD, Kim K, Ren SG, Lewis I, Weckbecker G, Bruns C, Melmed S. The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion. J Clin Endocrinol Metab 2004; 89: 3027-3032.
39. Burris TP, Nguyen DN, Smith SG, Freeman ME. The stimulatory and inhibitory effects of dopamine on prolactin secretion involve different G-proteins. Endocrinology 1992; 130: 926-932.
40. Denef C, Manet D, Dewals R. Dopaminergic stimulation of prolactin release. Nature 1980; 285: 243-246.
41. Kineman RD, Gettys TW, Frawley LS. Paradoxical effects of dopamine (DA): Gi alpha 3 mediates DA inhibition of PRL release while masking its PRL-releasing activity. Endocrinology 1994; 135: 790-793.
42. Gruszka A, Ren SG, Dong J, Culler MD, Melmed S. Regulation of growth hormone and prolactin gene expression and secretion by chimeric somatostatin-dopamine molecules. Endocrinology 2007; 148: 6107-6114.
43. Zatelli MC, Piccin D, Tagliati F, Bottoni A, Ambrosio MR, Margutti A, Scanarini M, Bondanelli M, Culler MD, degli Uberti EC. Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro. J Mol Endocrinol 2005; 35: 333-341.
44. Fletcher TP, Thomas GB, Clarke IJ. Growth hormone-releasing hormone and somatostatin concentrations in the hypophysial portal blood of conscious sheep during the infusion of growth hormone-releasing peptide-6. Domest Anim Endocrinol 1996; 13: 251-258.
45. Drisko JE, Faidley TD, Zhang D, McDonald TJ, Nicolich S, Hora DF, Cunningham P, Li C, Rickes E, McNamara L, Chang C, Smith RG, Hickey GJ. Administration of a nonpeptidyl growth hormone secretagogue, L-163, 255, changes somatostatin pattern, but has no effect on patterns of growth hormone-releasing factor in the hypophyseal-portal circulation of the conscious pig. Proc Soc Exp Biol Med 1999; 222: 70-77.
46. Plotsky PM, Vale W. Patterns of growth hormone-releasing factor and somatostatin secretion into the hypophysial-portal circulation of the rat. Science 1985; 230: 461-463.
47. Tannenbaum GS, Painson JC, Lengyel AM, Brazeau P. Paradoxical enhancement of pituitary growth hormone (GH) responsiveness to GH-releasing factor in the face of high somatostatin tone. Endocrinology 1989; 124: 1380-1388.
48. Cella SG, Luceri M, Cattaneo L, Torsello A, Muller EE. Somatostatin withdrawal as generator of pulsatile GH release in the dog: a possible tool to evaluate the endogenous GHRH tone? Neuroendocrinology 1996; 63: 481-488.
49. Dickerman Z, Guyda H, Tannenbaum GS. Pretreatment with somatostatin analog SMS 201-995 potentiates growth hormone (GH) responsiveness to GH-releasing factor in short children. J Clin Endocrinol Metab 1993; 77: 652-657.
50. Adams EF, Brajkovich IE, Mashiter K. Growth hormone and prolactin secretion by dispersed cell cultures of a normal human pituitary: effects of thyrotrophin releasing hormone, theophylline, somatostatin, and 2-bromo-alpha-ergocryptine. Acta Endocrinol (Copenh) 1981; 98: 345-351.
51. Rene E, Willoughby J, Brazeau P. Differentiation between the somatostatin inhibition and the post-somatostatin rebound observed on growth hormone secretion in vitro. Regul Pept 1982; 4: 325-331.
52. Henry BA, Rao A, Tilbrook AJ, Clarke IJ. Chronic food-restriction alters the expression of somatostatin and growth hormone-releasing hormone in the ovariectomised ewe. J Endocrinol 2001; 170: R1-R5.
53. Luque RM, Gahete MD, Hochgeschwender U, Kineman RD. Evidence that endogenous SST inhibits ACTH and ghrelin expression by independent pathways. Am J Physiol Endocrinol Metab 2006; 291: E395-E403.
54. Muller AF, Lamberts SW, Janssen JA, Hofland LJ, Koetsveld PV, Bidlingmaier M, Strasburger CJ, Ghigo E, Van der Lely AJ. Ghrelin drives GH secretion during fasting in man. Eur J Endocrinol 2002; 146: 203-207.
55. Colao A, Auriemma RS, Lombardi G, Pivonello R. Resistance to somatostatin analogs in acromegaly. Endocr Rev 2010; 32: 247-271.